Molecular characterization of a B-ring unsaturated estrogen: Implications for conjugated equine estrogen components of Premarin

Steroids

Volumn 73, Issue 1, 2008, Pages 59-68

  Hsieh, Robert W ^a,b   Rajan, Shyamala S ^a   Sharma, Sanjay K ^a   Greene, Geoffrey L ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Conjugated equine estrogens; Estrogen receptor structure; Estrogens; Hormone replacement therapy; Premarin

Indexed keywords

17BETA METHYL 17ALPHA DIHYDROEQUILENIN; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HISTIDINE; HYDROXYL GROUP; LIGAND; NCI 122; NUCLEAR RECEPTOR COACTIVATOR 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL LINE; CELL STRAIN COS7; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ESTROGEN ACTIVITY; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROPHOBICITY; NONHUMAN; PROTEIN DOMAIN; STRUCTURE ANALYSIS;

CARRIER PROTEINS; CELL LINE, TUMOR; DIMERIZATION; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; ESTROGENS, CONJUGATED (USP); HUMANS; HYDROGEN BONDING; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NERVE TISSUE PROTEINS; PROTEIN BINDING; RECEPTORS, ANDROGEN; TRANSCRIPTION, GENETIC;

EQUIDAE;

EID: 36849074651     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2007.08.014     Document Type: Article

References (34)

1. Hersh A.L., Stefanick M.L., and Stafford R.S. National use of post-menopausal hormone therapy: annual trends and response to recent evidence. JAMA 291 1 (2004) 47-53
2. Stefanick M.L. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med 118 12 Suppl. 2 (2005) 64-73
3. Anderson G.L., Limacher M., Assaf A.R., Bassford T., Beresford S.A., Black H., et al. Effects of conjugated equine estrogen in post-menopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 14 (2004) 1701-1712
4. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the Women's Health Initiative randomized controlled trial. Jama 288 3 (2002) 321-333
5. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 1998; 19(1) p.61-109.
6. Petitti D.B., Perlman J.A., and Sidney S. Noncontraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol 70 3 Pt. 1 (1987) 289-293
7. Stampfer M.J., Willett W.C., Colditz G.A., Rosner B., Speizer F.E., and Hennekens C.H. A prospective study of post-menopausal estrogen therapy and coronary heart disease. N Engl J Med 313 17 (1985) 1044-1049
8. Bush T.L., Barrett-Connor E., Cowan L.D., Criqui M.H., Wallace R.B., Suchindran C.M., et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 75 6 (1987) 1102-1109
9. Henderson B.E., Paganini-Hill A., and Ross R.K. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol 159 2 (1988) 312-317
10. Bhavnani B.R. Estrogens and menopause: pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer's. J Steroid Biochem Mol Biol 85 2-5 (2003) 473-482
11. Heldring N., Pike A., Andersson S., Matthews J., Cheng G., Hartman J., et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 87 3 (2007) 905-931
12. Hsieh R.W., Rajan S.S., Sharma S.K., Guo Y., DeSombre E.R., Mrksich M., et al. Identification of ligands with bicyclic scaffolds provides insights into mechanisms of estrogen receptor subtype selectivity. J Biol Chem 281 26 (2006) 17909-17919
13. Monroe D.G., Getz B.J., Johnsen S.A., Riggs B.L., Khosla S., and Spelsberg T.C. Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERalpha or ERbeta. J Cell Biochem 90 2 (2003) 315-326
14. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276 (1997) 307-326
15. Vagin A., and Teplyakov A. MOLREP: an automated program for molecular replacement. J Appl Crystallogr 30 (1997) 1022-1025
16. McRee D.E. XtalView/Xfit-a versatile program for manipulating atomic coordinates and electron density. J Struct Biol 125 2-3 (1999) 156-165
17. Brunger A.T. Free R-value-a novel statistical quantity for assessing the accuracy of crystal-structures. Nature 355 6359 (1992) 472-475
18. Murshudov G.N., Vagin A.A., and Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D: Biol Crystallogr 53 Pt 3 (1997) 240-255
19. Esnouf R.M. An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. J Mol Graph Model 15 2 (1997) 132-134
20. Merritt E.A., and Bacon D.J. Raster3D: photorealistic molecular graphics. Methods Enzymol 277 (1997) 505-524
21. Guex N., and Peitsch M.C. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18 15 (1997) 2714-2723
22. Warnmark A., Treuter E., Gustafsson J.A., Hubbard R.E., Brzozowski A.M., and Pike A.C. Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor alpha. J Biol Chem 277 24 (2002) 21862-21868
23. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 7 (1998) 927-937
24. Anstead G.M., Carlson K.E., and Katzenellenbogen J.A. The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 62 3 (1997) 268-303
25. Anstead G.M., and Kym P.R. Benz[a]anthracene diols: predicted carcinogenicity and structure-estrogen receptor binding affinity relationships. Steroids 60 5 (1995) 383-394
26. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 6652 (1997) 753-758
27. Shiau A.K., Barstad D., Radek J.T., Meyers M.J., Nettles K.W., Katzenellenbogen B.S., et al. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol 9 5 (2002) 359-364
28. Ray D.W., Suen C.S., Brass A., Soden J., and White A. Structure/function of the human glucocorticoid receptor: tyrosine 735 is important for transactivation. Mol Endocrinol 13 11 (1999) 1855-1863
29. Stevens A., Garside H., Berry A., Waters C., White A., and Ray D. Dissociation of steroid receptor coactivator 1 and nuclear receptor corepressor recruitment to the human glucocorticoid receptor by modification of the ligand-receptor interface: the role of tyrosine 735. Mol Endocrinol 17 5 (2003) 845-859
30. Nettles K.W., Sun J., Radek J.T., Sheng S., Rodriguez A.L., Katzenellenbogen J.A., et al. Allosteric control of ligand selectivity between estrogen receptors alpha and beta: implications for other nuclear receptors. Mol Cell 13 3 (2004) 317-327
31. Bhavnani B.R., Cecutti A., Gerulath A., Woolever A.C., and Berco M. Comparison of the antioxidant effects of equine estrogens, red wine components, vitamin E, and probucol on low-density lipoprotein oxidation in post-menopausal women. Menopause 8 6 (2001) 408-419
32. Subbiah M.T., Kessel B., Agrawal M., Rajan R., Abplanalp W., and Rymaszewski Z. Antioxidant potential of specific estrogens on lipid peroxidation. J Clin Endocrinol Metab 77 4 (1993) 1095-1097
33. Bhavnani B.R., Berco M., and Binkley J. Equine estrogens differentially prevent neuronal cell death induced by glutamate. J Soc Gynecol Invest 10 5 (2003) 302-308
34. Zhang Y., Lu X., and Bhavnani B.R. Equine estrogens differentially inhibit DNA fragmentation induced by glutamate in neuronal cells by modulation of regulatory proteins involved in programmed cell death. BMC Neurosci 4 (2003) 32